论文部分内容阅读
目的比较两种胰岛素制剂(甘精胰岛素与NPH胰岛素)治疗2型糖尿病的有效性和安全性。方法在延安大学附属医院2006～2008年门诊及住院病人中抽取100名2型糖尿病患者,随机分为两组,分别给予在口服药物的基延础上加用甘精胰岛素(LANTUS-来得时)和NPH胰岛素(诺和灵N),治疗12周。结果甘精胰岛素组患者的空腹血糖(FPG)和糖化血红蛋白(HbA1c)水平较低,且甘精胰岛素组患者症状性低血糖的发生率明显减少。结论口服降糖药基础上,加用甘精胰岛素比NPH更适合作为2型糖尿病患者的基础胰岛素治疗。
Objective To compare the efficacy and safety of two insulin preparations (insulin glargine and NPH insulin) in the treatment of type 2 diabetes mellitus. Methods A total of 100 patients with type 2 diabetes were selected from outpatients and inpatients from 2006 to 2008 in the Affiliated Hospital of Yan’an University. Patients were randomly divided into two groups. Patients were given insulin glargine (LANTUS-LIT) on the basis of oral drug, And NPH insulin (Novolin N) for 12 weeks. Results The fasting blood glucose (FPG) and glycosylated hemoglobin (HbA1c) were lower in patients with insulin glargine, and the incidence of symptomatic hypoglycemia was significantly decreased in patients with insulin glargine. Conclusions Oral hypoglycemic agents, based on the addition of insulin glargine NPN more suitable for type 2 diabetes patients with basal insulin therapy.